• Epidemiology and risk stratification in healthy and sick population
  • Expanding the target population for anti-platelet/coagulation therapy
  • Controversial issues: from clinical studies to real life
  • Sport and cardiac pathologies
  • Nuclear cardiology in CAD and CHF patients
Acute Coronary Syndromes
  • Evolving therapies for Acute myocardial Infarction: when PTCA, when stent?
  • Hybrid myocardial revascularization
  • Post-ACS patient’s route
  • Anti-thrombotic therapy in STEMI and NSTEMI patient
  • Management of STEMI and non-STEMI patient
  • New antiplatelet drugs
  • BioResorbable Vascular Scaffold update in interventional cardiology
  • Spinal Cord Stimulation in refractory CAD: still an appropriate choice?
  • Chronic Ischemic artery disease: dignaostic pathways and therapeutical algorythms
Global Cardiovascular Risk Prevention
  • Global Cardiovascular Risk assessment and prevention
  • Insulin Resistance Syndrome, type 2 Diabetes and Atherosclerosis: an explosive mixture
  • Lipid-lowering therapy: do we need statins for all life long?
  • Diagnosis and treatment of patients with hypercholesterolemia : update
  • New drugs for treating resistant hypercholesterolemia
  • PCSK9i and clinical outcomes
  • Role of platelets in the atherosclerosis pathogenesis
  • Drug interaction, gender, age and comorbidities
  • Elderly and Cardiology: are all patients to be treated the same way?
  • Right pharmacological therapy in fragile patient
Echocardiography & Imaging
  • Echocardiography in the evaluation of the induced AF-mechanical remodelling
  • Evaluation of thromboembolic atrial sources
  • Echo optimisation of atrial-ventricular delay in paced AF patients
  • Doppler echocardiography in the management of the resynchronization in HF
  • Consensus Documents on Imaging and coronary anatomy
Heart Failure
  • The interaction of AF and CHF and its clinical implications
  • Neurohumoral activation in CHF patients
  • Latest pharmacological therapy for CHF
  • The HF doctor: is there still a role for clinical cardiologists?
  • What lessons from the early completed trials?
  • Management of hypertrophic and dilated cardiomyopathy
  • Biomarkers in HF
  • Management and diagnostic pathways for HF ambulatory network
Non-Invasive Risk Stratification
  • New non-invasive markers for risk stratification
  • Syncope: practical issues of diagnosis and treatment
  • Physical treatment of neurally-mediated syncope
  • Organizational models of Syncope Unit
  • Modern management of chest pain and unexplained palpitations
  • The new generation implantable loop recorders
Hypertrophic Cardiomyopathy
  • ...
New Guidelines in Cardiology
  • ...